SQZ Biotechnologies Company (SQZB)
OTCMKTS
· Delayed Price · Currency is USD
0.0280
0.00 (0.00%)
Mar 28, 2025, 4:00 PM EST
SQZB Revenue
SQZ Biotechnologies Company had revenue of $12.12M in the twelve months ending September 30, 2023, down -44.62% year-over-year. In the year 2022, SQZ Biotechnologies Company had annual revenue of $21.48M, down -20.74%.
Revenue (ttm)
12.12M
Revenue Growth
-44.62%
P/S Ratio
0.07
Revenue / Employee
228.70K
Employees
53
Market Cap
825.75K
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 21.48M | -5.62M | -20.74% |
Dec 31, 2021 | 27.10M | 6.10M | 29.05% |
Dec 31, 2020 | 21.00M | 889.00K | 4.42% |
Dec 31, 2019 | 20.11M | 7.44M | 58.73% |
Dec 31, 2018 | 12.67M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.76B |
SS Innovations International | 16.04M |
Veradigm | 588.02M |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 200.90M |
Northwest Biotherapeutics | 1.60M |
Silence Therapeutics | 43.26M |
American Oncology Network | 1.76B |
SQZ Biotechnologies Company News
- 1 year ago - STEMCELL Technologies Announces Successful Asset Purchase Agreement with SQZ Biotechnologies Company - Business Wire
- 1 year ago - Asset Sale and Plan of Liquidation and Dissolution Approved by SQZB Shareholders - Business Wire
- 1 year ago - SQZ Biotechnologies Reports Third Quarter 2023 Financial Results and Recent Portfolio Updates - Business Wire
- 1 year ago - SQZ Biotechnologies Reports Data for Clinical Programs at the Society for Immunotherapy of Cancer Annual Meeting - Business Wire
- 1 year ago - SQZ Biotechnologies Reports Second Quarter 2023 Financial Results and Recent Portfolio Updates - Business Wire
- 1 year ago - SQZ Biotechnologies Provides Update on Collaboration with Roche - Business Wire